Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer

Trial Profile

An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Acronyms EFFECT
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Sep 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 01 Jun 2015 Planned End Date changed from 1 May 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top